MetaVia Inc. announced that data from its Phase 1 trial of DA-1726, a dual GLP-1 and glucagon receptor agonist, will be presented at the Precision Liver Symposium 2026. DA-1726 demonstrated significant weight loss, reduction in liver fat, and preservation of lean mass in the trial, highlighting its potential for treating cardiometabolic diseases. The drug acts by reducing appetite and increasing energy expenditure, showing promising results compared to existing treatments in preclinical studies. MetaVia is advancing DA-1726 and another drug, vanoglipel, targeting metabolic and liver diseases, with further clinical development planned.
MetaVia's DA-1726 clinical trial data presentation coincides with a health sector market where 42 of 150 US stocks rose and 97 fell on Pluang. Notable movers include Boston Scientific Corporation (BSX) with a price of USD 39.07 and a 1-day change of -13.29%, GE HealthCare Technologies Inc. (GEHC) at USD 77.00 with +8.28%, and BioNano Genomics Inc. (BNGO) at USD 1.12 with -8.20%. This snapshot is as of Oct 28, 2026 19:11 WIB.
Circuit Mind has introduced AVE (Agentic Verification Engine), an AI-powered application that verifies printed circuit board (PCB) schematics against datasheets and internal design rules to catch errors early and avoid expensive respins. AVE compleme...
Grabar Law Office is investigating claims against officers and directors of Erasca, Planet Fitness, PROCEPT BioRobotics, and The Simply Good Foods Company for alleged breaches of fiduciary duties. The investigations focus on misleading statements and...
Circuit Mind secured $25 million in funding, including an $18.5 million Series A led by Norwest, to expand its AI platform that automates and optimizes electronic circuit board design. The platform helps companies reduce design time by up to 90%, cut...
Alvotech, a global biotech company specializing in biosimilars, will release its financial results for the first nine months of 2026 on November 11 after U.S. market close. A live webcast presentation is scheduled for November 12 at noon, where manag...
Sampo Oyj will publish its financial results for the first nine months of 2026 on November 4, 2026, at around 8:30 AM. Alongside the report, supplementary presentation materials will be available on their website. An investor conference call will be ...
